Screening for Gynecologic Cancers

Cervical Cancer Screening - Pap Patrol Power

• Goal: Detect & treat precancerous lesions (Cervical Intraepithelial Neoplasia - CIN) and early invasive cancer, reducing morbidity/mortality.
• Screening Modalities:
  • Cytology (Pap Smear): Liquid-Based Cytology (LBC) preferred. Results via Bethesda System (e.g., ASC-US, LSIL, HSIL).
  • HPV DNA Testing: Detects high-risk HPV (hrHPV). Preferred primary screening method globally.
  • Visual Inspection with Acetic Acid (VIA) / Lugol’s Iodine (VILI): Cost-effective for low-resource settings.
• Key Guidelines (India - MOHFW/FOGSI):
  • Target Age: 30-65 years.
  • HPV Test (Preferred): Every 5 years.
  • Pap Smear: Every 3 years.
  • VIA/VILI: Every 5 years (where HPV/Pap not feasible).
• WHO: Recommends hrHPV testing from age 30 (every 5-10 yrs) or cytology/VIA (every 3 yrs). Stop at 65 with adequate negative history.

⭐ Persistent infection with high-risk HPV types, primarily HPV 16 and 18, is responsible for over 70% of cervical cancers.

Ovarian Cancer Screening - Elusive Egg Snatchers

• No effective population screening for asymptomatic, average-risk women; leads to more harm than benefit.
• Challenges: Low incidence, lack of pre-malignant stage, poor specificity of CA-125 & Transvaginal Sonography (TVS) in general population.
• High-Risk Groups (Genetic Predisposition):
  • BRCA1 mutation: Lifetime risk ~40-50%.
  • BRCA2 mutation: Lifetime risk ~15-25%.
  • Lynch syndrome (HNPCC): Risk ~5-12%.
  • Strong family history.
• Management in High-Risk:
  • Screening: Consider CA-125 & TVS every 6 months from age 30-35 (or 5-10 yrs before earliest familial diagnosis).
  • Risk-Reducing Salpingo-oophorectomy (RRSO): Recommended after childbearing, typically ages 35-40 for BRCA1, 40-45 for BRCA2. Reduces ovarian cancer risk by >80%.

⭐ The majority of high-grade serous ovarian cancers, the most common type, are now thought to originate in the fimbrial end of the fallopian tube (Serous Tubal Intraepithelial Carcinoma - STIC).

Endometrial Cancer Screening - Womb Wellness Watch

No routine population screening. Focus on symptomatic & high-risk individuals.

• Primary Symptom for Investigation: Postmenopausal Bleeding (PMB).
• High-Risk Groups (Consider Screening/Early Investigation):
  • Lynch Syndrome (HNPCC): Annual TVS & endometrial biopsy from age 30-35.
  • History of unopposed estrogen therapy.
  • Tamoxifen use (monitor for PMB, routine ET screening not standard).
  • Obesity, PCOS, diabetes, nulliparity.
• PMB Evaluation Pathway:
  • Initial: Transvaginal Sonography (TVS).
    • Endometrial Thickness (ET) ≤ 4mm: Low risk if bleeding resolves. Re-evaluate if PMB persists/recurs.
    • ET > 4mm (or any thickness if on Tamoxifen & PMB): Endometrial biopsy.
  • Gold Standard: Endometrial Biopsy (e.g., Pipelle, D&C).

⭐ Any postmenopausal bleeding (PMB) is considered endometrial cancer until proven otherwise; it's the presenting symptom in >90% of cases.

High‑Yield Points - ⚡ Biggest Takeaways

• Cervical Cancer: Pap smear (ages 21-29, every 3 years). Ages 30-65: Co-testing (Pap+HPV DNA) every 5 years or Pap alone every 3 years.
• HPV Vaccination: Crucial for primary prevention of most cervical cancers.
• Ovarian Cancer: No routine screening for average-risk women. CA-125 & TVS considered for high-risk (e.g., BRCA).
• Endometrial Cancer: No routine screening. Postmenopausal bleeding (PMB) is a red flag. Annual biopsy for Lynch syndrome.
• Vulvar/Vaginal Cancers: No specific population screening; often detected via routine pelvic exam findings.